Clinicians managing women’s bone health navigate a condition shaped by hormonal transitions, reproductive history, and cumulative risk factors. Women experience earlier and more frequent osteoporosis than men, driven primarily by postmenopausal oestrogen decline, which accelerates bone resorption in the first 5–10 years after menopause.
NICE guidance (CG146, with ongoing updates) recommends fracture risk assessment using tools such as FRAX or QFracture for women aged 65 and over, and earlier in the presence of risk factors including prior fragility fracture, early menopause, corticosteroid exposure, low BMI, smoking, alcohol, and family history. Bone mineral density measurement refines risk where indicated.
Fracture Liaison Services (FLS) provide a structured secondary prevention pathway, identifying patients post-fracture, assessing underlying osteoporosis, and initiating treatment. Evidence supports reduced re-fracture rates with coordinated FLS models, originally pioneered locally in Glasgow in the late 1990s through clinician-charity collaboration before wider NHS adoption. National audits reveal variable coverage and gaps in identification, referral, and monitoring.
BOAST standards for older or frail orthopaedic trauma patients emphasise comprehensive assessment, timely imaging, and clear communication with primary care and FLS teams. Adherence varies, particularly for vertebral fractures, which are frequently under-recognised or poorly communicated between radiology, orthopaedics, and primary care.
Pregnancy-associated osteoporosis is rare; case series link it to low BMI, nutritional issues, or steroids, with fractures often in late antenatal or early postnatal periods. Menopause consultations offer a key window to integrate bone health discussion, risk assessment, and lifestyle advice. Digital templates and risk calculators must accurately capture sex-specific factors like early menopause or steroid history to avoid underestimation.
Challenges include diagnostic overshadowing in women with multimorbidity, geographic variation in FLS access, and historical under-representation of diverse populations in research. Improvements underway include expanded FLS programmes, updated NICE thresholds, radiology prompts, and better integration with menopause pathways.
Links to related pages: See our clinical summaries on informed consent and risk communication and service transitions across women’s life stages.
References
- NICE CG146 and QS149. Available at: https://www.nice.org.uk.
- Royal Osteoporosis Society Clinical Quality Hub and FLS resources. Available at: https://theros.org.uk.
- British Orthopaedic Association BOAST guidelines. Available at: https://www.boa.ac.uk.
- NHS England FLS Toolkit and FLS Database audits.
- Relevant Cochrane reviews on pharmacological and non-pharmacological interventions.
Mandatory disclaimer This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.